ETFs positioned on Ligand Pharmaceuticals Incorporated

Name YTD change Weight AuM
+20.77% - 2,098 M€
+18.87%2.72% 23 M€
+25.35%2.54% 513 M€
+19.32%2% 520 M€
+27.66%1.81% 107 M€
+0.48%1.23% 250 M€
+29.07%1.19% 184 M€
+15.32%1.17% 258 M€
+30.89%1.01% 1,631 M€
+9.38%0.88% 54 M€
+29.90%0.83% 46 M€
+14.75%0.76% 297 M€
+10.62%0.67% 3,143 M€
+13.71%0.62% 7 M€
+34.27%0.52% 989 M€
+10.31%0.5% 23 M€
+26.62%0.43% 1,260 M€
+24.39%0.43% 200 M€
+20.61%0.38% 156 M€
+2.19%0.36% 1,528 M€
+7.32%0.35% 462 M€
+21.02%0.35% 3,154 M€
-0.08%0.32% 17 M€
+14.03%0.3% 605 M€
+26.33%0.29% 1,079 M€
+26.22%0.29% 78 M€
+25.65%0.28% 81 M€
+16.82%0.28% 8,387 M€
+17.41%0.27% 257 M€
+14.23%0.25% 626 M€
+21.67%0.25% 75 M€
+9.04%0.25% 37 M€
+21.24%0.25% 3,276 M€
0.00%0.25% 27 M€
+17.01%0.25% 112,456 M€
+17.95%0.25% 4,367 M€
-.--%0.24% 10 M€
+16.98%0.24% 5,200 M€
+16.95%0.23% 8,373 M€
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
  1. Stock Market
  2. Stocks
  3. LGND Stock
  4. ETFs Ligand Pharmaceuticals Incorporated